GLP1R and type 2 diabetes mellitus: Therefore, using a large, real-world population with type 2 diabetes, we constructed a model to assess the cost-effectiveness of widespread use of SGLT2is and GLP-1 RAs in people with type 2 diabetes, considering only major cardiovascular and kidney outcomes.